

SCORE Search Results Details for Application 10578781 and Search Result 20081104_154454_us-10-578-781-1.rng.

Score Home	Retrieve Application	SCORE System	SCORE	Comments /
Page	List	Overview	FAQ	Suggestions

This page gives you Search Results detail for the Application 10578781 and Search Result 20081104_154454_us-10-578-781-1.rng.

[Go Back to previous page](#)

GenCore version 6.3
Copyright (c) 1993 - 2008 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 4, 2008, 17:10:32 ; Search time 243 Seconds
(without alignments)
44258.760 Million cell updates/sec

Title: US-10-578-781-1
Perfect score: 756
Sequence: 1 at gggg gccgat at caaaaa.....aggagcaaatt gaacatt ag 756

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 11806651 seqs, 7113014948 residues

Total number of hits satisfying chosen parameters: 23613302

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_200808: *

- 1: geneseqn1980s: *
- 2: geneseqn1990s: *
- 3: geneseqn2000: *
- 4: geneseqn2001a: *
- 5: geneseqn2001b: *
- 6: geneseqn2002a: *
- 7: geneseqn2002b: *
- 8: geneseqn2003a: *
- 9: geneseqn2003b: *
- 10: geneseqn2003c: *
- 11: geneseqn2003d: *
- 12: geneseqn2004a: *
- 13: geneseqn2004b: *
- 14: geneseqn2004c: *
- 15: geneseqn2004d: *
- 16: geneseqn2004e: *
- 17: geneseqn2004f: *
- 18: geneseqn2005a: *
- 19: geneseqn2005b: *
- 20: geneseqn2005c: *
- 21: geneseqn2006a: *

22: geneseqn2006b: *
 23: geneseqn2006c: *
 24: geneseqn2006d: *
 25: geneseqn2007a: *
 26: geneseqn2007b: *
 27: geneseqn2007c: *
 28: geneseqn2007d: *
 29: geneseqn2008: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	756	100.0	756	18	AEA00728	Aea00728 Brevibacterium
2	273.4	36.2	665	6	ABK78469	Abk78469 Bacillus
3	192.2	25.4	1438	12	ADN60500	Adn60500 B. lichen
4	178.2	23.6	777	21	Aeh93992	Aeh93992 SigG codi
5	173.8	23.0	381	6	ABK74144	Abk74144 Bacillus
6	147	19.4	631	6	ABK74048	Abk74048 Bacillus
7	78	10.3	1110	12	ADH97013	Adh97013 S. pneumo
8	78	10.3	1110	18	AEC13368	Aec13368 Streptoco
9	76.4	10.1	915	12	ADK44581	Adk44581 Streptoco
10	76.4	10.1	915	21	AEJ68509	Aej68509 Streptoco
11	76.4	10.1	915	21	AEJ75484	Aej75484 Streptoco
12	76.4	10.1	915	21	AEJ82844	Aej82844 Streptoco
13	76.4	10.1	915	21	AEL05163	Ael05163 Streptoco
14	76.4	10.1	915	21	AEL12413	Ael12413 Streptoco
15	76.4	10.1	915	21	AEL50821	Ael50821 Streptoco
16	76.4	10.1	915	25	AEM07844	Aem07844 Streptoco
17	76.4	10.1	915	25	AEM66066	Aem66066 Streptoco
18	76.4	10.1	915	25	AEM86645	Aem86645 Streptoco
19	76.4	10.1	915	25	AGI20663	Agi20663 Streptoco
20	76.4	10.1	915	25	AEN48202	Aen48202 Streptoco
21	76.4	10.1	915	25	AEN55537	Aen55537 Streptoco
22	76.4	10.1	915	25	AEN40434	Aen40434 Streptoco
23	76.4	10.1	915	25	AGI76906	Agi76906 Streptoco
24	76.4	10.1	915	25	AEN08741	Aen08741 Streptoco
25	76.4	10.1	915	25	AGV09876	Agv09876 Streptoco
26	76.4	10.1	915	25	AGV21123	Agv21123 Streptoco
27	76.4	10.1	915	25	AJE78366	Aje78366 Streptoco
28	76.4	10.1	915	25	AJE70154	Aje70154 Streptoco
29	76.4	10.1	915	25	AJE86340	Aje86340 Streptoco
30	76.4	10.1	915	25	AJE95472	Aje95472 Streptoco
31	76.4	10.1	915	25	AJE61089	Aje61089 Streptoco
32	76.4	10.1	915	25	AGV40930	Agv40930 Streptoco
33	76.4	10.1	915	25	AGV46355	Agv46355 Streptoco
34	76.4	10.1	915	25	AJF01903	Ajf01903 Streptoco
35	76.4	10.1	915	25	AJF07993	Ajf07993 Streptoco
36	76.4	10.1	915	25	AJF13317	Ajf13317 Streptoco
37	76.4	10.1	915	25	AJF53284	Ajf53284 Streptoco
38	76.4	10.1	915	25	AJF18960	Ajf18960 Streptoco
39	76.4	10.1	915	25	AJG97788	Ajg97788 Streptoco
40	76.4	10.1	915	25	ALK14103	Alk14103 S. pneumon
41	76.4	10.1	915	25	ALT08207	Alt08207 Streptoco
42	76.4	10.1	915	25	ANK69294	Ank69294 Streptoco
43	76.4	10.1	915	25	ANJ76477	Anj76477 S. pneumo
44	76.4	10.1	915	25	ANK74634	Ank74634 Streptoco
45	76.4	10.1	915	26	ANN03548	Ann03548 S. pneumo

ALIGNMENTS

RESULT 1

AEA00728

ID AEA00728 standard; DNA; 756 BP.

XX

AC AEA00728;

XX

DT 28-JUL-2005 (first entry)

XX

DE Brevibacillus choshinensis DNA #1.

XX

KW Cell culture; Brevibacillus choshinensis; gene; ds.

XX

OS Brevibacillus choshinensis.

XX

FH Key Location/Qualifiers

FT CDS

FT

FT

XX

PN W02005045005-A1.

XX

PD 19-MAY-2005.

XX

PF 08-NOV-2004; 2004W0-JP016912.

XX

PR 11-NOV-2003; 2003JP-00381606.

XX

PA (HGET) HIGETA SHOYU KK.

XX

PI Hanagata H, Nishijyo T;

XX

DR WPI; 2005-366840/37.

DR

XX

PT New Brevibacillus choshinensis, that does not form spores and which shows
 PT low extracellular or intracellular protease activity, useful as host for
 PT producing recombinant protein.

XX

PS Claim 4; SEQ ID NO 1; 103pp; Japanese.

XX

CC The invention relates to a Brevibacillus choshinensis HPD31-SP3 (FERMBP-
 CC 08479), which does not form spores and which has mycological
 CC characteristics such as cell size and rod shape and physiological
 CC characteristics such as negative for nitrate reduction and positive for
 CC citric acid utilization, oxidase and catalase, and showing low
 CC extracellular protease activity. The invention also relates to a
 CC transformed B. choshinensis using a vector containing the gene encoding
 CC the protein of the invention. B. choshinensis is useful as a host for
 CC producing a recombinant protein and for producing a protein by culturing
 CC a transformed host. It has decreased extracellular protein degradation
 CC activity when compared with other strains. This sequence represents B.
 CC choshinensis DNA of the invention.

XX

SQ Sequence 756 BP; 207 A; 166 C; 211 G; 172 T; 0 U; 0 Other;

Query Match 100.0% Score 756; DB 18; Length 756;

Best Local Similarity 100.0% Pred. No. 3e-234;

Matches 756; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 ATGGGTGCGGATATCAAAAATGCGAGTCAACCATTTCTGACCAATGACCAAGTGAAAGAT 60
          |||
Db      1 ATGGGTGCGGATATCAAAAATGCGAGTCAACCATTTCTGACCAATGACCAAGTGAAAGAT 60

Qy     61 TTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAAT 120
          |||
Db     61 TTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAAT 120

Qy    121 ATCAGACTGGTCTGGTCCGTCCAGCGCTTTATCAACCCGCGGTATGAAGCGGATGAT 180
          |||
Db    121 ATCAGACTGGTCTGGTCCGTCCAGCGCTTTATCAACCCGCGGTATGAAGCGGATGAT 180

```

Qy	181	TTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGGCGGTTGACAAGTTCGATCTTTTGTAC	240
Db	181	TTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGGCGGTTGACAAGTTCGATCTTTTGTAC	240
Qy	241	GATGTGAGATTTTTCGACCTATGCGGTGCCAATGATCATCGGAGAAATTCACGCTTTTTTG	300
Db	241	GATGTGAGATTTTTCGACCTATGCGGTGCCAATGATCATCGGAGAAATTCACGCTTTTTTG	300
Qy	301	CGCGATGACGGTACGGTTAAGGTCAGTCGATCGTTAAAAGAAACAGCGAATAAGGTGCGG	360
Db	301	CGCGATGACGGTACGGTTAAGGTCAGTCGATCGTTAAAAGAAACAGCGAATAAGGTGCGG	360
Qy	361	CGATCAAAGGATGAATTGTACAAGCAATTCGGCGGTGCCCCACGATCGCAGAAAGTGGCA	420
Db	361	CGATCAAAGGATGAATTGTACAAGCAATTCGGCGGTGCCCCACGATCGCAGAAAGTGGCA	420
Qy	421	GAAGCAGTGGGAATCAOGCGGAGGAAGTAGTCTTTGCGCAAGAGGCAAGCAGAGCGCCT	480
Db	421	GAAGCAGTGGGAATCAOGCGGAGGAAGTAGTCTTTGCGCAAGAGGCAAGCAGAGCGCCT	480
Qy	481	TCCTCCATCCATGAGACCGTTTTTTGAAAATGACGGCGATCCCATCACACTGATCGATCAG	540
Db	481	TCCTCCATCCATGAGACCGTTTTTTGAAAATGACGGCGATCCCATCACACTGATCGATCAG	540
Qy	541	ATAGCGGATGAAGGTGTGAACAAGTGGTTTGAGAAAATTGCCTTGAAGGACGCCATCAGC	600
Db	541	ATAGCGGATGAAGGTGTGAACAAGTGGTTTGAGAAAATTGCCTTGAAGGACGCCATCAGC	600
Qy	601	AGGCTGAGCGAGCGTGAGCAGCTCATCGTCTACCTGCGCTATTACAAGGATCAGACACAG	660
Db	601	AGGCTGAGCGAGCGTGAGCAGCTCATCGTCTACCTGCGCTATTACAAGGATCAGACACAG	660
Qy	661	TCTGAGGTAGCAGAGCGTCTAGGGATTTGCGAGGTCCAGGTCTCGCGTCTGGAAAAGCGT	720
Db	661	TCTGAGGTAGCAGAGCGTCTAGGGATTTGCGAGGTCCAGGTCTCGCGTCTGGAAAAGCGT	720
Qy	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG	756
Db	721	ATCCTGCTAACGATCAAGGAGCAAATTGAACATTAG	756

RESULT 2

ABK78469

ID ABK78469 standard; DNA; 665 BP.

XX

AC ABK78469;

XX

DT 13- AUG- 2002 (first entry)

XX

DE Bacillus clausii genomic sequence tag (GST) #1312.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

OS Bacillus clausii.

XX

PN W0200229113- A2.

XX

PD 11- APR- 2002.

XX

PF 05- OCT- 2001; 2001W0- US031437.

XX

PR 06- OCT- 2000; 2000US- 00680598.

PR 27- MAR- 2001; 2001US- 0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

Query Match 36.2% Score 273.4; DB 6; Length 665;
Best Local Similarity 67.4% Pred. No. 1.9e-77;
Matches 399; Conservative 0; Mismatches 192; Indels 1; Gaps 1;

Qy 37 CTGACCAATGACCAAGTGAAAGATTTGATAGCCAAAGAGCCAAAGCTGGCGATACGGATGCA 96
Db 40 CTATCGATAAACAAGTGAAAGAGCTTATTGCAAAAAGGCAGGAAGGCGACACAGAAGCA 99

Qy 97 CGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTCCAGCGCTTTATC 156
Db 100 CGGGATTGATCGTCAACCATAACACACGTCTCGTCTGGTCAGTGGTTCAACGTTTTTTTG 159

Qy 157 AACCGGGGATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGGCC 216
Db 160 AATCGGGTATGAGGCAGATGACCTTTTTCAAATTGGCTGCATTGGTTAATTAAGTCT 219

Qy 217 GTTGACAAGTTCGATCTTTTCGTACGATGTGAGATTTTCGAOCTATGCGGTGCCAATGATC 276
Db 220 GTCGACAAATTTGACCTTTCCTACGACGTGAAATTTTCCACGTATGCTGTGCGGATGATT 279

Qy 277 ATCGGAGAAATTCACGCTTTTTTGCGCGATGACGGTACGGTTAAGGTCAGTCGATCGTTA 336
Db 280 ATTGGTGAAATCCAACGGTTTCTGCGGGATGATGGCACAGTGAAAGTAAGCCGGTCCATT 339

Qy 337 AAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAATTCGGCCGT 396
Db 340 AAAGAATTAAAGCAATAAAATCCGCAAAAGCAAAAGACGAAGTACGAAAACGCTGCGGCGG 399

Qy 397 GCGCCACGATCGCAGAAGTGCCAGAAACAGTGGGAATCAOCCCGGAGGAAGTAGTCTTT 456
Db 400 GCACCGACCATTAATGAGATCGCTGAACATTTAGGCGTGAOCCCTGAGGAAATTGTATTT 459

Qy 457 GCGCAAGAGGCAAGCAGAGCGGCTTCTCCATCCATGAGACCGTTTTTTGAAATGACGGC 516

```

Db      460  GCTGGAGATGCCAACCGGAGCTTGTCTCAATCCATGAAACGGTTTATGAAAATGACGGC 519
Qy      517  GATCCCATCACACTGATCGATCAGATAGCGGATGAAGGTGTGAACAAGTGGTTTGAGAAA 576
Db      520  GATCCGATTACACTTCTAGATCAAATTGCCGAOCCACTCACAAGTCAAATGGTTTGACAAG 579
Qy      577  ATTGCCTTGAAGGACGCCATCAGCAGGCTGAGCGAGCGTGAGCAGCTCATCG 628
Db      580  ATTG CTTTAAAGAAGCGATTTGCGACCTTGGCGANAGGGAGCGGCTAATTG 630

```

RESULT 3

ADN60500

ID ADN60500 standard; DNA; 1438 BP.

XX

AC ADN60500;

XX

DT 01-JUL-2004 (first entry)

XX

DE B. licheniformis sporulation related polynucleotide, seq id 172.

XX

KW Mutant host cell; sporulation; oxidoreductase; transferase; hydrolase;
KW lyase; isomerase; ligase; gene; ds.

XX

OS Bacillus licheniformis.

XX

PN WD2003087148-A2.

XX

PD 23-OCT-2003.

XX

PF 25-MAR-2003; 2003WD-DK000200.

XX

PR 10-APR-2002; 2002DK-00000533.

XX

PA (NOVO) NOVOZYMES AS.

XX

PI Andersen JT, Jorgensen ST, Rasmussen MD, Cisen PB, Clausen IG;

XX

DR WPI; 2004-122131/12.

DR

P-PSDB; ADN60501.

XX

PT A Bacillus licheniformis mutant host cell for producing a product of

PT

interest e.g. vitamins, antibiotics and enzymes.

XX

PS Claim 1; SEQ ID NO 172; 319pp; English.

XX

CC The invention relates to a Bacillus licheniformis mutant host cell
 CC derived from a parent B. licheniformis host cell. The mutant host cell is
 CC mutated in one or more genes encoding one or more polypeptides involved
 CC in sporulation. The host cell comprises one or more heterologous genes
 CC present in at least two copies, encoding one or more heterologous
 CC polypeptides. The heterologous genes are stably integrated into the
 CC genome of the cell without leaving any antibiotic resistance marker genes
 CC at the site of integration. The heterologous genes are transcribed from a
 CC heterologous promoter or from an artificial promoter, and are comprised
 CC in an operon, preferably a polycistronic operon. The heterologous
 CC polypeptide is an antimicrobial peptide, or a fusion peptide comprising a
 CC peptide part which in its native form has antimicrobial activity. The
 CC heterologous polypeptide is an enzyme, preferably a secreted enzyme. The
 CC enzyme is an enzyme of a class selected from the group of enzyme classes
 CC consisting of oxidoreductases (EC 1), transferases (EC 2), hydrolases (EC
 CC 3), lyases (EC 4), isomerases (EC 5), and ligases (EC 6). The Bacillus
 CC licheniformis is useful in a process for producing at least one product
 CC of interest, comprising cultivating a B. licheniformis mutant host cell
 CC in a suitable medium whereby the said product is produced. The process
 CC further comprises isolating or purifying the product of interest. The
 CC current sequence represents a B. licheniformis sporulation related
 CC polynucleotide.

XX

SQ Sequence 1438 BP; 421 A; 324 C; 355 G; 338 T; 0 U; 0 Other;

Query Match 25.4% Score 192.2; DB 12; Length 1438;
 Best Local Similarity 63.7% Pred. No. 7.1e-51;
 Matches 309; Conservative 0; Mismatches 173; Indels 3; Gaps 1;

```

Qy      1 ATGGGTGCGGATATCAAAAATGCGAGTCAACCATTTCTGACCAATGACC--AAGTGAAA 57
      |||
Db    954 ATGGATGTGGAGGTTAAAAAAGAAAACCGAACAACCTCAGCTTAAAGACCATGAAGTGAAA 1013
      |||
Qy      58 GATTTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGC 117
      |||
Db   1014 GAACTGATTA AAAACAGCCAGAACGGCGATCAAAAAGCAAGGGACCTCCTCATAGAAAAA 1073
      |||
Qy     118 AATATCAGACTGGTCTGGTGGTGGTCCAGCGCTTTATCAACCGCGGGTATGAAGCGGAT 177
      |||
Db   1074 AACATGCGTCTTGTTTGGTCTGTGGTTCAGCGTTTTTTGAACAGAGGCTATGAGCCTGAC 1133
      |||
Qy     178 GATTTGTTTCAGATOGGTTGCATTGGCTTGCTCAAGGCGGTTGACAAGTTGATCTTTTCG 237
      |||
Db   1134 GACCTCTTTCAAATCGGCTGCATCGGCTCTTGAAGTCGGTGGACAAATTCGATCTTTTC 1193
      |||
Qy     238 TACGATGTGAGATTTTGAOCTATGCGGTGCCAATGATCATCGGAGAAATTCACGCTTT 297
      |||
Db   1194 TATGACGTTGCGTTTTCAOCTACGCGGTTCCGATGATTATCGGCGAGATTCAGCGGTTT 1253
      |||
Qy     298 TTGCGCGATGACGGTAOGGTTAAGGTCAGTCGATCGTTAAAAGAAACAGCGAATAAGGTG 357
      |||
Db   1254 ATCAGAGATGACGGAACCGTCAAAGTGAGCCGCTCGCTGAAAGAACTCGGCAACAAAATC 1313
      |||
Qy     358 CGGCGATCAAAGGATGAATTGTACAAGCAATTGCGCGTGCCCCCAOGATCGCAGAAAGTG 417
      |||
Db   1314 CGGCGGGCGAAAGACGAGCTTCCAAGTCAAACGGCGGATTCCGACCGTTCCAGGAAATC 1373
      |||
Qy     418 GCAGAAGCAGTGGGAATCACGCGGAGGAAGTAGTCTTTGCCAAGAGGCAAGCAGAGCG 477
      |||
Db   1374 GCGGATTATCTCGAAATCAGTTCAGAAGAGGTGCTGATGGGCCAGGAAGCGGTCCGCTCT 1433
      |||
Qy     478 CCTTC 482
      |||
Db   1434 CCTTC 1438
  
```

RESULT 4

AEH93992

ID AEH93992 standard; cDNA; 777 BP.

XX

AC AEH93992;

XX

DT 27-JUL-2006 (first entry)

XX

DE SigG coding sequence.

XX

KW ss; gene; protein production; sigma factor; RNA polymerase;

KW alkaline protease; food.

XX

OS Bacillus sp.; KSM-9865.

XX

FH Key Location/Qualifiers

FT CDS

1..777

FT

/*tag= a

FT

/product= "SigG"

XX

PN JP2006136221-A.

XX

PD 01-JUN-2006.

XX

PF 10-NOV-2004; 2004JP-00326973.

XX
 PR 10- NOV- 2004; 2004JP- 00326973.
 XX
 PA (KAOS) KAO CORP.
 XX
 PI Sumitomo N, Okuda T, Takimura Y, Sato T, Kobayashi T;
 XX
 DR WPI ; 2006- 385028/ 40.
 DR P- PSDB; AEH93994.
 XX
 PT Novel sporulation related gene encoding SigE protein or SigG protein
 PT having alkaline protease activity, useful in foodstuffs such as alcoholic
 PT beverage, bean paste, soy sauce, pharmaceuticals and cosmetics.
 XX
 PS Claim 1; SEQ ID NO 2; 15pp; Japanese.
 XX
 CC This sequence represents the SigG sequence which encodes the sigma factor
 CC which is a subunit of RNA polymerase. A microorganism transformed with
 CC the SigE or SigG sequence is useful for producing a protein or
 CC polypeptide having alkaline protease activity. The sigma peptides are
 CC useful in foodstuffs e.g. alcoholic beverage, bean paste, soy sauce,
 CC pharmaceuticals and cosmetics. The protein having alkaline protease
 CC activity can be produced efficiently using non-sporulated microorganisms.
 XX
 SQ Sequence 777 BP; 264 A; 123 C; 189 G; 201 T; 0 U; 0 Other;

Query Match 23.6% Score 178.2; DB 21; Length 777;
 Best Local Similarity 53.9% Pred. No. 1.8e-46;
 Matches 391; Conservative 0; Mismatches 328; Indels 6; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
      |||
Db      49 OCTGTTTTGAAGAATGAAGAAATGCGGAAGTTATTTCTGTAATGCAAGGCGGAGAACTT 108
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGCTCCAGGCG 150
      |||
Db     109 TCTGCAAGAGAAAAGCTCGTGAATGGGAACCAAAGGCTCGTTCTAAGTGTTATTCAACGG 168
Qy     151 TTTATCAACCGCGGGTATGAAGGGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db     169 TTTAACAACCGTGGTGAATTTGTAGATGACTTATTTCAAGTAGGCTGCATCGGGTTAATG 228
Qy     211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
      |||
Db     229 AAGTCGATTGATAATTTTGACCTGGGTGAGAATGTTAAGTTTTCTACATATGCAGTAOCA 288
Qy     271 ATGATCATCGGAGAAATTCACGCTTTTTGCGCGATGACGGTACGGTTAAGGTCAGTGA 330
      |||
Db     289 ATGATAATCGGGGAGATAAGGCGCTATCTACGAGATAATAATCCGATCAGGGTATCCGCG 348
Qy     331 TCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAATTC 390
      |||
Db     349 TCATTGGTGATATTGCTACAAGGCGCTGCAGGTGAGGAAAAGGCTGATGAGTGAAACA 408
Qy     391 GGCCTGTGCCCCACGATCGCAGAAAGTGGCAGAAGCAGTGGGAATCAAGCGGAGGAAGTA 450
      |||
Db     409 TCAAGGGAGGCTACCGCAGAAGAAATTTCAAAAGTACTTGAAGTACCGCATGAGGAGATT 468
Qy     451 GTCTTTGCGCAAGAGGCAAGCAGAGCGGCTTCCTCCATCCATGAGACCGTTTTTTGAAAAT 510
      |||
Db     469 GTTTTTGCTTTAAATGCTATTGAGGATCCCGTGTCTTATTTGAGGCTATCTATAATGAT 528
Qy     511 GACGCGGATCCCATCAGACTGATCGATCAGATAGCGGATGAAGGTGTGAA- - - - - CAAG 564
      |||
Db     529 GGTGGAGATCCGATTTATGTATTGGATCAAATCAGTGACGAAAAGAACAAGATATCCAA 588
Qy     565 TGGTTTGAGAAAATTGCTTGAAGGACGCCATCAGCAGGCTGAGCGAGCGTGAGCAGCTC 624
      |||
Db     589 TCGATAGAAGAGATAGCACTAAAAGAAGGTATGAGACGTCTCAATGACAGGGAAAAGCTC 648

```



```

Qy      625  ATCGTCTACCTGCGCTATTACAAGGATCAGACACAGTCTGAGGTAGCAGAGCGTCTAGGG 684
          |||||
Db      649  ATTTTAAGAAAACGGTTTTTCAAGGGAAAACGCAAATGGAAGTAGCTGATGAAATCGGG 708
Qy      685  ATTTGCGAGGTCCAGGTCTGCGTCTGGAAAAGCGTATCCTGCTAAGCATCAAGGAGCAA 744
          |||||
Db      709  ATATCGCAAGCACAAAGTGTCAAGACTTGAAAAGGCTGCAATCAAACAGATGAATAAAAAT 768
Qy      745  ATTGA 749
          |||||
Db      769  ATTCA 773

```

RESULT 5

ABK74144

ID ABK74144 standard; DNA; 381 BP.

XX

AC ABK74144;

XX

DT 13- AUG- 2002 (first entry)

XX

DE Bacillus licheniformis genomic sequence tag (GST) #1435.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

OS Bacillus licheniformis.

XX

PN WD200229113- A2.

XX

PD 11- APR- 2002.

XX

PF 05- OCT- 2001; 2001WD- US031437.

XX

PR 06- OCT- 2000; 2000US- 00680598.

PR

27- MAR- 2001; 2001US- 0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA

(NOVO) NOVOZYMES AS.

XX

PI Berka R, Clausen IG;

XX

DR WPI ; 2002- 416684/ 44.

XX

PT Monitoring differential expression of several genes in first Bacillus
PT cell relative to expression of same genes in one or more second Bacillus
PT cells, by using substrate containing Bacillus genomic sequenced tag
PT array.

XX

PS Claim 4; SEQ ID NO 1435; 200pp; English.

XX

CC The invention describes a method of monitoring differential expression of
CC genes in a first Bacillus cell relative to expression of the genes in
CC other Bacillus cells, comprising hybridising labelled nucleic acid probes
CC isolated from Bacillus cells to a substrate containing array of Bacillus
CC genomic sequenced tags (GST), examining the array, and determining
CC relative gene expression by an observed hybridisation reporter signal of
CC a spot in the array. The method is useful for measuring the expression of
CC genes in a first Bacillus cell relative to expression of the same genes
CC in one or more second Bacillus cells. The method is useful for monitoring
CC global expression of several genes from a Bacillus cell, discovering new
CC genes, identifying possible functions of unknown open reading frames and
CC monitoring gene copy number variation and stability. Monitoring changes
CC in expression of genes may be used to provide a representation of the way
CC in which Bacillus cells adapt to changes in culture conditions,
CC environmental stress or other physiological provocation. Extensive follow
CC -up characterisation is unnecessary, when one spot on an array equals one

CC gene or one open reading frame, since sequence information is available.
 CC This sequence represents a genomic sequence tag (GST) used in the method
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from WPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 381 BP; 109 A; 91 C; 94 G; 87 T; 0 U; 0 Other;

Query Match 23.0% Score 173.8; DB 6; Length 381;
 Best Local Similarity 66.9% Pred. No. 3.4e-45;
 Matches 247; Conservative 0; Mismatches 122; Indels 0; Gaps 0;

```

Qy      50 AAGTAAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACGGATGCACGTGAGCTTCTCG 109
      |||
Db      13 AAGTAAAAGAACTGATTAATAACAGCCAGAACGGCGATCAAAAAGCAAGGGACCTCCTCA 72
Qy     110 TGAATAGCAATATCAGACTGGTCTGGTCCGTCGTCCAGCGCTTTATCAACCGCGGGTATG 169
      |||
Db      73 TAGAAAAAACATGCGTCTTGTTTGGTCTGTGCGTTCAGCGTTTTTTGAACAGAGGCTATG 132
Qy     170 AAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTCAAGGCGGTTGACAAGTTCTG 229
      |||
Db     133 AGCCTGACGACCTCTTTCAAATCGGCTGCATCGGCCTCTTGAAGTCGGTGGACAAATTCG 192
Qy     230 ATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCAATGATCATCGGAGAAATTC 289
      |||
Db     193 ATCTTTCCTATGACGTTTCGGTTTTCCACCTACGCGTTCCGATGATTATCGGCGAGATTC 252
Qy     290 AACGCTTTTTTGCGCGATGAOGGTACGGTTAAGGTCAGTCGATCGTTAAAAGAAACAGCGA 349
      |||
Db     253 AGCGGTTTATCAGAGATGAOGGAACCGTCAAAGTGAGCGCGCTCGCTGAAAGAACTCGGCA 312
Qy     350 ATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAATTCCGCCGTGCCCCCAOGATCG 409
      |||
Db     313 ACAAAATCCGGCGGGCGAAAGAGAGCTTTCAGAGTCAAACCGCGCGATTCCGACCGTTTC 372
Qy     410 CAGAAAGTGG 418
      |||
Db     373 AGGAAATCG 381
  
```

RESULT 6

ABK74048

ID ABK74048 standard; DNA; 631 BP.

XX

AC ABK74048;

XX

DT 13- AUG- 2002 (first entry)

XX

DE Bacillus licheniformis genomic sequence tag (GST) #1339.

XX

KW Differential gene expression; genomic sequenced tag; GST;

KW altered culture condition; environmental stress;

KW physiological provocation; ds.

XX

OS Bacillus licheniformis.

XX

PN WO200229113- A2.

XX

PD 11- APR- 2002.

XX

PF 05- OCT- 2001; 2001WO- US031437.

XX

PR 06- OCT- 2000; 2000US- 00680598.

PR 27- MAR- 2001; 2001US- 0279526P.

XX

PA (NOVO) NOVOZYMES BIOTECH INC.

PA (NOVO) NOVOZYMES AS.

XX

PI Berka R, Clausen IG;

XX

DR

WPI; 2002-416684/44.

XX

PT

Monitoring differential expression of several genes in first Bacillus cell relative to expression of same genes in one or more second Bacillus cells, by using substrate containing Bacillus genomic sequenced tag array.

PT

XX

PS

Claim 4; SEQ ID NO 1339; 200pp; English.

XX

CC

The invention describes a method of monitoring differential expression of genes in a first Bacillus cell relative to expression of the genes in other Bacillus cells, comprising hybridising labelled nucleic acid probes isolated from Bacillus cells to a substrate containing array of Bacillus genomic sequenced tags (GST), examining the array, and determining relative gene expression by an observed hybridisation reporter signal of a spot in the array. The method is useful for measuring the expression of genes in a first Bacillus cell relative to expression of the same genes in one or more second Bacillus cells. The method is useful for monitoring global expression of several genes from a Bacillus cell, discovering new genes, identifying possible functions of unknown open reading frames and monitoring gene copy number variation and stability. Monitoring changes in expression of genes may be used to provide a representation of the way in which Bacillus cells adapt to changes in culture conditions, environmental stress or other physiological provocation. Extensive follow-up characterisation is unnecessary, when one spot on an array equals one gene or one open reading frame, since sequence information is available. This sequence represents a genomic sequence tag (GST) used in the method of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ

Sequence 631 BP; 203 A; 121 C; 161 G; 146 T; 0 U; 0 Other;

Query Match 19.4% Score 147; DB 6; Length 631;
Best Local Similarity 56.8% Pred. No. 2.3e-36;
Matches 270; Conservative 0; Mismatches 205; Indels 0; Gaps 0;

```

Qy      77 AAGCTGGCGATACGGATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGT 136
      |||
Db      98 ATGAAGGAGACACAACAGCGAGAGAAAAGCTTGTTAAGCGCAATTTGCGCCTTGCTTAA 157

Qy     137 CCGTCGTCCAGCGCTTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTT 196
      |||
Db     158 GCGTCATTCAAAGGTTTAACAACAGAGGAGAATATGTTGATGACTTATTCOAAGTCGGCT 217

Qy     197 GCATTGGCTTGCTCAAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTGA 256
      |||
Db     218 GCATCGGACTAATGAAATCAATTGATAATTTTGACCTGAGCCACAATGTTAAGTTTTCAA 277

Qy     257 CCTATGCGGTGCCAATGATCATCGGAGAAATTCAACGCTTTTTTGCGCGATGACGGTAACG 316
      |||
Db     278 CATATGCTGTACCAATGATCATCGGAGAAATCGGCAGATATTTGCGCGATAACAACCCGA 337

Qy     317 TTAAGGTCAGTCGATCGTTAAAAGAAACAGCGAATAAGGTGCGCGCATCAAAGGATGAAT 376
      |||
Db     338 TCGCGTCTCACGGTCACTCAGGGATATCGCGTACAAGGCGCTGCAAGTGAGAGAACGGC 397

Qy     377 TGTACAAGCAATTCGGCCGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCA 436
      |||
Db     398 TGATCAGTGAGACAAGCAGGGAGCCGACTGCTCAGGAGATCGCTAAAGAGCTTGAAGTGT 457

Qy     437 CGCCGGAGGAAGTAGTCTTTGCGCAAGAGGCAAGCAGAGCGCCTTCCTCCATCCATGAGA 496
      |||
Db     458 CCCATGAAGAAATCGTTTTTGCGCTTGACGOCATTCAAGATCCTGTATCTTTGTTTGAGC 517

Qy     497 CCGTTTTTGAAAATGACGGCGATCCCATCAGACTGATCGATCAGATAGCGGATGA 551
      |||

```

Db 518 CGATTTACAATGACGGAGGAGATCCGATTTATGTCATGGATCAAATCAGCGATGA 572

RESULT 7

ADH97013

ID ADH97013 standard; DNA; 1110 BP.

XX

AC ADH97013;

XX

DT 06-MAY-2004 (first entry)

XX

DE S. pneumoniae RNA polymerase sigma-70 factor gene #2.

XX

KW antibacterial; antiinflammatory; gastrointestinal; antiulcer;

KW antidiarrhoeic; ophthalmological; enzyme inhibitor; antisense therapy;

KW vaccine; microbial target; modulator; furuncle; pneumonia; gastritis;

KW peptic ulcer disease; diarrhoea; meningitis; bacteraemia; conjunctivitis;

KW toxic shock syndrome; gene; ds.

XX

CS Streptococcus pneumoniae.

XX

PN WC2003102190-A2.

XX

PD 11-DEC-2003.

XX

PF 02-JUN-2003; 2003WD-CA000786.

XX

PR 31-MAY-2002; 2002US-0384634P.

PR 31-MAY-2002; 2002US-0385157P.

PR 04-JUN-2002; 2002US-0385542P.

PR 04-JUN-2002; 2002US-0385611P.

PR 04-JUN-2002; 2002US-0385747P.

PR 04-JUN-2002; 2002US-0385750P.

PR 04-JUN-2002; 2002US-0385752P.

PR 04-JUN-2002; 2002US-0385773P.

PR 04-JUN-2002; 2002US-0385780P.

PR 04-JUN-2002; 2002US-0385785P.

PR 04-JUN-2002; 2002US-0385797P.

PR 05-JUN-2002; 2002US-0385962P.

PR 05-JUN-2002; 2002US-0386022P.

PR 05-JUN-2002; 2002US-0386024P.

PR 05-JUN-2002; 2002US-0386087P.

PR 05-JUN-2002; 2002US-0386141P.

PR 05-JUN-2002; 2002US-0386350P.

PR 05-JUN-2002; 2002US-0386586P.

PR 06-JUN-2002; 2002US-0386368P.

PR 06-JUN-2002; 2002US-0386369P.

PR 06-JUN-2002; 2002US-0386436P.

PR 06-JUN-2002; 2002US-0386441P.

PR 06-JUN-2002; 2002US-0386528P.

PR 06-JUN-2002; 2002US-0386573P.

PR 06-JUN-2002; 2002US-0386834P.

PR 31-JUL-2002; 2002US-0399839P.

PR 31-JUL-2002; 2002US-0399861P.

PR 31-JUL-2002; 2002US-0399969P.

PR 31-JUL-2002; 2002US-0399970P.

PR 31-JUL-2002; 2002US-0399983P.

PR 31-JUL-2002; 2002US-0399984P.

PR 31-JUL-2002; 2002US-0399985P.

PR 01-AUG-2002; 2002US-0400154P.

PR 01-AUG-2002; 2002US-0400230P.

PR 01-AUG-2002; 2002US-0400268P.

PR 01-AUG-2002; 2002US-0400363P.

PR 01-AUG-2002; 2002US-0400365P.

PR 01-AUG-2002; 2002US-0400374P.

PR 01-AUG-2002; 2002US-0400380P.

PR 01-AUG-2002; 2002US-0400433P.

PR 01-AUG-2002; 2002US-0400434P.

PR 01-AUG-2002; 2002US-0400436P.

PR 01- AUG- 2002; 2002US- 0400442P.
PR 01- AUG- 2002; 2002US- 0400463P.

XX (AFFI -) AFFI NI UM PHARM I NC.

PI Edwards A, Dharamsi A, Vedadi M, Vallee F, Awrey D, Beattie B;
PI Richards D, Domagala M, Mansoury K, Virag C, Buzadzija K;
PI McDonald M, Houston S, Arrowsmith C, Quyang H, Nethery K, Ng I;
PI Kanagarajah D;

XX
DR WPI ; 2004- 071165/ 07.
DR P- PSDB; ADH97014.

XX
PT Compositions comprising recombinant polypeptide targets for pathogenic
PT bacteria, useful for designing modulators for preventing or treating a
PT disease or disorder associated with the species of origin for the
PT polypeptide.

XX
PS Claim 23; SEQ ID NO 204; 606pp; English.

XX
CC The invention relates to novel compositions (I) comprising isolated,
CC recombinant polypeptides, amino acid sequences having at least about 95%
CC identity with these or an amino acid sequence encoded by a polynucleotide
CC that hybridizes under stringent conditions to the complementary strand of
CC the polynucleotide encoding these polypeptides. The compositions and
CC polypeptides are useful as microbial targets for designing modulators for
CC the prevention or treatment of a disease or disorder associated with the
CC species of origin for the polypeptide, e.g. furuncle, pneumonia,
CC gastritis, peptic ulcer disease, diarrhoea, meningitis, bacteraemia,
CC conjunctivitis or toxic shock syndrome. The polypeptides are also useful
CC for diagnosing a patient suffering from a disease or disorder of a
CC pathogenic species, or for monitoring the effectiveness of an anti-
CC pathogenic treatment. This sequence corresponds to one of the DNA
CC sequences of the invention

SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;

Query Match 10.3% Score 78; DB 12; Length 1110;
Best Local Similarity 50.7% Pred. No. 8.1e-14;
Matches 214; Conservative 0; Mismatches 205; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATAACG 90
      |||
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTCGTCCAGCGC 150
      |||
Db      388 GAAGCCAAACAACGTCTTGCGGAACGCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
Qy      151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db      448 TATGTCGGTCGTGGCATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy      211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGOGGTGCCA 270
      |||
Db      508 AAGGCGGTTGACAAGTTTGACTATTCTAAAGGGTCAAGTTTTCAACTTATGCAACTTGG 567
Qy      271 ATGATCATCGGAGAAAT- - -TCAACGCTTTTTGCGGATGACGGTACGGTTAAGGTCAGT 327
      |||
Db      568 TGGATTGTCAGGCTATCACTCGTGCTATTGCGGACCAAGCTCGTACCATCGTATCCCA 627
Qy      328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db      628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACACCGGAATCTCCTTCAAGAA 687
Qy      388 TTCGGCGGTGCCCCACGATCGCAGAAGTGCCAGAAGCAGTGGGAATCACGCGGAGGAA 447
      |||
Db      688 TTGGGCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACAOCTGATAAG 747

```

Qy 448 GT 449
 ||
 Db 748 GT 749

RESULT 8

AEC13368

ID AEC13368 standard; DNA; 1110 BP.

XX

AC AEC13368;

XX

DT 20-OCT-2005 (first entry)

XX

DE Streptococcus pneumoniae RNA polymerase sigma-70 factor gene.

XX

KW protein purification; antibacterial; antimicrobial; infection;

KW drug screening; RNA polymerase sigma-70 factor; gene; ss.

XX

OS Streptococcus pneumoniae.

XX

PN US2005181464-A1.

XX

PD 18-AUG-2005.

XX

PF 29-SEP-2004; 2004US-00953901.

XX

PR 04-APR-2002; 2002US-0369819P.

PR 04-APR-2002; 2002US-0369826P.

PR 04-APR-2002; 2002US-0369831P.

PR 04-APR-2002; 2002US-0370060P.

PR 08-APR-2002; 2002US-0370681P.

PR 08-APR-2002; 2002US-0370806P.

PR 08-APR-2002; 2002US-0370852P.

PR 08-APR-2002; 2002US-0370868P.

PR 09-APR-2002; 2002US-0370959P.

PR 09-APR-2002; 2002US-0370978P.

PR 09-APR-2002; 2002US-0371008P.

PR 09-APR-2002; 2002US-0371009P.

PR 09-APR-2002; 2002US-0371014P.

PR 09-APR-2002; 2002US-0371025P.

PR 09-APR-2002; 2002US-0371064P.

PR 09-APR-2002; 2002US-0371065P.

PR 09-APR-2002; 2002US-0371094P.

PR 09-APR-2002; 2002US-0371114P.

PR 09-APR-2002; 2002US-0371180P.

PR 09-APR-2002; 2002US-0371189P.

PR 31-MAY-2002; 2002US-0384634P.

PR 31-MAY-2002; 2002US-0385157P.

PR 04-JUN-2002; 2002US-0385542P.

PR 04-JUN-2002; 2002US-0385611P.

PR 04-JUN-2002; 2002US-0385747P.

PR 04-JUN-2002; 2002US-0385750P.

PR 04-JUN-2002; 2002US-0385752P.

PR 04-JUN-2002; 2002US-0385773P.

PR 04-JUN-2002; 2002US-0385780P.

PR 04-JUN-2002; 2002US-0385785P.

PR 04-JUN-2002; 2002US-0385797P.

PR 05-JUN-2002; 2002US-0385962P.

PR 05-JUN-2002; 2002US-0386022P.

PR 05-JUN-2002; 2002US-0386024P.

PR 05-JUN-2002; 2002US-0386087P.

PR 05-JUN-2002; 2002US-0386141P.

PR 05-JUN-2002; 2002US-0386350P.

PR 05-JUN-2002; 2002US-0386586P.

PR 06-JUN-2002; 2002US-0386368P.

PR 06-JUN-2002; 2002US-0386369P.

PR 06-JUN-2002; 2002US-0386436P.

PR 06-JUN-2002; 2002US-0386441P.

PR 06-JUN-2002; 2002US-0386528P.

PR 06- JUN- 2002; 2002US- 0386573P.
 PR 06- JUN- 2002; 2002US- 0386834P.
 PR 31- JUL- 2002; 2002US- 0399839P.
 PR 31- JUL- 2002; 2002US- 0399861P.
 PR 31- JUL- 2002; 2002US- 0399969P.
 PR 31- JUL- 2002; 2002US- 0399970P.
 PR 31- JUL- 2002; 2002US- 0399983P.
 PR 31- JUL- 2002; 2002US- 0399984P.
 PR 31- JUL- 2002; 2002US- 0399985P.
 PR 01- AUG- 2002; 2002US- 0400154P.
 PR 01- AUG- 2002; 2002US- 0400230P.
 PR 01- AUG- 2002; 2002US- 0400268P.
 PR 01- AUG- 2002; 2002US- 0400363P.
 PR 01- AUG- 2002; 2002US- 0400365P.
 PR 01- AUG- 2002; 2002US- 0400374P.
 PR 01- AUG- 2002; 2002US- 0400380P.
 PR 01- AUG- 2002; 2002US- 0400433P.
 PR 01- AUG- 2002; 2002US- 0400434P.
 PR 01- AUG- 2002; 2002US- 0400436P.
 PR 01- AUG- 2002; 2002US- 0400442P.
 PR 01- AUG- 2002; 2002US- 0400463P.
 PR 04- APR- 2003; 2003WO- CA000465.
 PR 08- APR- 2003; 2003WO- CA000482.
 PR 08- APR- 2003; 2003WO- CA000483.
 PR 02- JUN- 2003; 2003WO- CA000786.

XX

PA (AFFI -) AFFI NI UM PHARM I NC.

XX

PI Edwards A, Dharamsi A, Vedadi M, Alam MZ, Arrowsmith C, Awrey DE;
 PI Beattie B, Buzadzija K, Clarke T, Domagala M, Houston S;
 PI Kanagarajah D, Li Q, Mansoury K, McDonald M, Nethery-Brooks K, Ng I;
 PI Qiyang H, Richards D, Vallee F, Virag C;

XX

DR WPI ; 2005-628190/64.

DR

P-PSDB; AEC13369.

XX

PT Novel crystallized, recombinant bacterial polypeptide, useful as targets
 PT for pathogenic bacteria such as *Helicobacter pylori*, *Staphylococcus*
 PT *aureus*, for detecting pathogenic species in biological sample, and in
 PT drug designing.

XX

PS Claim 85; SEQ ID NO 204; 637pp; English.

XX

CC The invention relates to a composition (I) comprising purified
 CC polypeptides from bacteria. Also described: (1) a crystallized,
 CC recombinant polypeptide comprising an amino acid sequence of (I), where
 CC the polypeptide is in crystal form (2) a crystallized complex comprising
 CC the crystallized, recombinant polypeptide and a co-factor or a small
 CC organic molecule, where the complex is in crystal form; and (3) a host
 CC cell comprising a nucleic acid encoding a polypeptide of (I), where a
 CC culture of the host cell produces at least about 1 mg of the polypeptide
 CC per liter of culture and the polypeptide is at least about one-third
 CC soluble as measured by gel electrophoresis. (I) can be used as a target
 CC for pathogenic bacteria, useful for detecting the presence of a
 CC pathogenic species in a biological sample. (I) is useful for monitoring
 CC the effectiveness of anti-pathogenic treatments in an individual
 CC suffering from a disease or disorder caused by a pathogenic bacteria,
 CC such as infections. (I) is also useful in drug design and screening, for
 CC identifying inhibitors of (I), for designing a potential compound that is
 CC useful for treating or preventing pathogenic diseases or disorders, for
 CC assessing the activity of small molecules and other modulators in in
 CC vitro assay, and for developing antimicrobial agents. The present
 CC sequence represents a *Streptococcus pneumoniae* RNA polymerase sigma-70
 CC factor gene, which is used in an example from the present invention.

XX

SQ Sequence 1110 BP; 341 A; 211 C; 267 G; 291 T; 0 U; 0 Other;

Query Match 10.3% Score 78; DB 18; Length 1110;
 Best Local Similarity 50.7% Pred. No. 8.1e-14;

Matches 214; Conservative 0; Mismatches 205; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATAOG 90
      |||
Db      328 OCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
Qy      91 GATGCAOGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGCTCCAGCGC 150
      |||
Db      388 GAAGCCAAACAACGCTCTTGCGGAACGCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
Qy     151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db     448 TATGTCGGTGGTGGCATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy     211 AAGGCGGTTGACAAGTTCGATCTTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
      |||
Db     508 AAGGCGGTTGACAAGTTTGACTATTCTAAAGGGTTCAAGTTTCAACTTATGCAACTTGG 567
Qy     271 ATGATCATCGGAGAAAT- - -TCAACGCTTTTTGCGCGATGACGGTAACGGTTAAGGTCAGT 327
      |||
Db     568 TGGATTGTCAGGCTATCACTOGTGCTATTGCGGACCAAGCTCGTAACCATCGTATCCCA 627
Qy     328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db     628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA 687
Qy     388 TTGCGCGGTGCCCCACGATCGCAGAAGTGCCAGAAGCAGTGGGAATCACGCGGAGGAA 447
      |||
Db     688 TTGGGGCAAGATCCGACACCGAAGCAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
Qy     448 GT 449
      ||
Db     748 GT 749

```

RESULT 9

ADK44581

ID ADK44581 standard; DNA; 915 BP.

XX

AC ADK44581;

XX

DT 24-FEB-2005 (first entry)

XX

DE Streptococcus pneumoniae gene, Seq ID No 1096.

XX

KW ds; gene; Antibacterial; Gene therapy; Vaccine; Streptococcus pneumoniae.

XX

OS Streptococcus pneumoniae.

XX

PN US6699703-B1.

XX

PD 02-MAR-2004.

XX

PF 26-MAY-2000; 2000US-00583110.

XX

PR 02-JUL-1997; 97US-0051553P.

PR

PR 12-MAY-1998; 98US-0085131P.

PR

PR 30-JUN-1998; 98US-00107433.

XX

PA (GENO-) GENOME THERAPEUTICS CORP.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Houseweart CE;

XX

DR WPI; 2004-212399/20.

DR

DR P-PSDB; ADK47242.

XX

PT New nucleic acid molecules and polypeptides useful for diagnosing,

PT preventing and treating pathological conditions resulting from bacterial

PT infection, e.g. Streptococcus pneumoniae infection, and in drug

PT screening.
 XX
 PS Disclosure; SEQ ID NO 1096; 301pp; English.
 XX
 CC The invention relates to isolated *Streptococcus pneumoniae* nucleic acids
 CC and polypeptides. The nucleic acids and proteins are useful for
 CC diagnosing, preventing and treating pathological conditions resulting
 CC from bacterial infection, such as *S. pneumoniae* infection. These may also
 CC be used for drug screening procedures. The present sequence represents a
 CC *Streptococcus pneumoniae* nucleic acid of the invention. Note: The
 CC sequence data for this patent did not appear in the printed specification
 CC but was obtained in electronic format directly from USPTO at
 CC seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 12; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
          |||
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
          |||
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGCTCCAGCGC 150
          |||
Db      388 GAAGCCAAACAACGCTCTTGCGGAAGCCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
          |||
Qy      151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
          |||
Db      448 TATGTCGGTCGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
          |||
Qy      211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
          |||
Db      508 AAGGCGGTTGACAAGTTCGACTATTCTAAAGGGTCAAGTTTTCAACTTATGCAACTTGG 567
          |||
Qy      271 ATGATCATCGGAGAAATTCAACGCTTTTTGCGCGATGACG - - GTACGGTTAAGGTCAGT 327
          |||
Db      568 TGGATTGTCAGGCTATCACTCGTGCTATTGCAGACCAAGCTCGTACCATCGTATCCCA 627
          |||
Qy      328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
          |||
Db      628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACACCGGAATCTCCTTCAAGAA 687
          |||
Qy      388 TTCGGCGGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCGGAGGAA 447
          |||
Db      688 TTGGGCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACAOCTGATAAG 747
          |||
Qy      448 GT 449
          ||
Db      748 GT 749
  
```

RESULT 10

AEJ68509

ID AEJ68509 standard; DNA; 915 BP.

XX

AC AEJ68509;

XX

DT 05-OCT-2006 (first entry)

XX

DE *Streptococcus pneumoniae* strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; *Streptococcus pneumoniae* infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..915
 FT /*tag= a
 FT /product= "Streptococcus pneumoniae protein SEQ ID
 FT NO: 3757"
 XX
 PN US7074914- B1.
 XX
 PD 11- JUL- 2006.
 XX
 PF 30- DEC- 2004; 2004US- 00028099.
 XX
 PR 02- JUL- 1997; 97US- 0051553P.
 PR 12- MAY- 1998; 98US- 0085131P.
 PR 30- JUN- 1998; 98US- 00107433.
 PR 26- MAY- 2000; 2000US- 00583110.
 PR 14- AUG- 2003; 2003US- 00640833.
 XX
 PA (SNFI) SANOFI PASTEUR LTEE.
 XX
 PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Houseweart CE;
 XX
 DR WPI; 2006- 500481/ 51.
 DR P- PSDB; AEJ71170.
 XX
 PT New isolated nucleic acid and polypeptide from Streptococcus pneumoniae,
 PT useful for diagnosing, preventing, or treating pathological conditions
 PT resulting from bacterial infections, e.g. S. pneumoniae infection.
 XX
 PS Example; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEJ68056),
 CC which encodes the Streptococcus pneumoniae protein of AEJ70717. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEJ67414- AEJ70074) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEJ70075- AEJ72735) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7074914B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

Qy 31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
 |||
 Db 328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387

```

Qy      91  GATGCAAGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGGTCCAGCGC 150
      |||
Db      388  GAAGCCAAACAACGTCTTGCGGAAGCCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
      |||
Qy      151  TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db      448  TATGTCCGTGGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
      |||
Qy      211  AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
      |||
Db      508  AAGGCGGTTGACAAGTTCGACTATTCTAAAGGGTCAAGTTTTCAACTTATGCAACTTGG 567
      |||
Qy      271  ATGATCATCGGAGAAATTCACGCTTTTTGCGCGATGACG - - GTACGGTTAAGGTCAGT 327
      |||
Db      568  TGGATTGGTCAGGCTATCACTCGTGCTATTGCAGACCAAGCTCGTACCATCGTATCCCA 627
      |||
Qy      328  CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db      628  GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA 687
      |||
Qy      388  TTCGGCCGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCCGGAGGAA 447
      |||
Db      688  TTGGGCCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
      |||
Qy      448  GT 449
      |||
Db      748  GT 749

```

RESULT 11

AEJ75484

ID AEJ75484 standard; DNA; 915 BP.

XX

AC AEJ75484;

XX

DT 05- OCT- 2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

CS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS

FT /*tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID

FT NO: 3757"

XX

PN US7081530-B1.

XX

PD 25- JUL- 2006.

XX

PF 30- DEC- 2004; 2004US- 00028291.

XX

PR 02- JUL- 1997; 97US- 0051553P.

PR 12- MAY- 1998; 98US- 0085131P.

PR 30- JUN- 1998; 98US- 00107433.

PR 26- MAY- 2000; 2000US- 00583110.

PR 14- AUG- 2003; 2003US- 00640833.

XX

PA (SNFI) SANOFI PASTEUR LTEE.

XX

PI Doucette- Stamm L, Bush D, Zeng Q, Opperman T, Houseweart CE;

XX

DR WPI ; 2006-518920/ 53.
 DR P- PSDB; AEJ78145.
 XX
 PT New isolated Streptococcus pneumoniae nucleic acid, useful as a molecular
 PT target for detecting, diagnosing, preventing, or treating a pathological
 PT condition resulting from bacterial infection.
 XX
 PS Example; SEQ ID NO 1096; 29pp; English.
 XX
 CC The invention relates to an isolated nucleic acid, especially (AEJ75443),
 CC which encodes the Streptococcus pneumoniae protein of AEJ78104. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEJ74389-AEJ77049) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEJ77050-AEJ79710) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7081530B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATAACG 90
      |||
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGCTCCAGCGC 150
      |||
Db      388 GAAGCCAAACAACGTCTTGCGGAAGCCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
Qy     151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db     448 TATGTCGGTCGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy     211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGOGGTGCCA 270
      |||
Db     508 AAGGCGGTTGACAAGTTTGACTATTCTAAAGGGTCAAGTTTCAACTTATGCAACTTGG 567
Qy     271 ATGATCATCGGAGAAATTCAACGCTTTTTGCGCGATGACG - - GTACGGTTAAGGTCAGT 327
      |||
Db     568 TGGATTGTCAGGCTATCACTCGTGCTATTGCAGACCAAGCTCGTACCATCGGTATCCCA 627
Qy     328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db     628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACACCGGAATCTCCTTCAAGAA 687
Qy     388 TTGCGCGGTGCCCCACGATCGCAGAAGTGCCAGAAGCAGTGGGAATCACGCGGAGGAA 447
      |||
Db     688 TTGGGCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACAOCTGATAAG 747

```

Qy 448 GT 449
 Db 748 GT 749

RESULT 12

AEJ82844

ID AEJ82844 standard; DNA; 915 BP.

XX

AC AEJ82844;

XX

DT 19-OCT-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS

1..915

FT

/*tag= a

FT

/product= "Streptococcus pneumoniae protein SEQ ID

FT

NO: 3757"

XX

PN US7098023- B1.

XX

PD 29-AUG-2006.

XX

PF 30-DEC-2004; 2004US-00027878.

XX

PR 02-JUL-1997; 97US-0051553P.

PR

12-MAY-1998; 98US-0085131P.

PR

30-JUN-1998; 98US-00107433.

PR

26-MAY-2000; 2000US-00583110.

PR

14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Houseweart CE;

XX

DR WPI; 2006-584390/60.

DR

P-PSDB; AEJ85505.

XX

PT New isolated Streptococcus pneumoniae nucleic acid and polypeptide,
 PT useful as vaccines and as targets for diagnosing, preventing, or treating
 PT pathological conditions resulting from S. pneumoniae bacterial infection.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEJ84330),
 CC which encodes the Streptococcus pneumoniae protein of AEJ86991. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEJ81749-AEJ84409) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEJ84410-AEJ87070) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus

CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation
 CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a Streptococcus pneumoniae strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7098023B1.
 XX
 SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
      |||
Db      328 OCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
Qy      91 GATGCAAGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGTCACGCGC 150
      |||
Db      388 GAAGCCAAACAACGTCTTGCGGAAGCCAATCTTCGTTTGGTTGTTTTCATTGCCAAACGC 447
Qy     151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db     448 TATGTGGTGGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy     211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
      |||
Db     508 AAGGCGGTTGACAAGTTCGACTATTCTAAAGGGTCAAGTTTTCAACTTATGCAACTTGG 567
Qy     271 ATGATCATCGGAGAAATTCACGCTTTTTGCGCGATGACG - - GTACGGTTAAGGTCAGT 327
      |||
Db     568 TGGATTGGTCAGGCTATCACTCGTGCTATTGCAGACCAAGCTCGTACCATCGTATCCCA 627
Qy     328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db     628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA 687
Qy     388 TTCGGCGGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCGGAGGAA 447
      |||
Db     688 TTGGGCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
Qy     448 GT 449
      ||
Db     748 GT 749
  
```

RESULT 13 AEL05163

ID AEL05163 standard; DNA; 915 BP.

XX

AC AEL05163;

XX

DT 30-NOV-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW

XX

CS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

CDS
 1. .915
 / * t a g = a
 / p r o d u c t = " S t r e p t o c o c c u s p n e u m o n i a e p r o t e i n S E Q I D
 N O : 3 7 5 7 "
 U S 7 1 1 5 7 3 1 - B 1 .
 0 3 - O C T - 2 0 0 6 .
 3 0 - D E C - 2 0 0 4 ; 2 0 0 4 U S - 0 0 0 2 7 3 9 9 .
 0 2 - J U L - 1 9 9 7 ; 9 7 U S - 0 0 5 1 5 5 3 P .
 1 2 - M A Y - 1 9 9 8 ; 9 8 U S - 0 0 8 5 1 3 1 P .
 3 0 - J U N - 1 9 9 8 ; 9 8 U S - 0 0 1 0 7 4 3 3 .
 2 6 - M A Y - 2 0 0 0 ; 2 0 0 0 U S - 0 0 5 8 3 1 1 0 .
 1 4 - A U G - 2 0 0 3 ; 2 0 0 3 U S - 0 0 6 4 0 8 3 3 .
 (S N F I) S A N O F I P A S T E U R L T D .
 D o u c e t t e - S t a m m L , B u s h D , Z e n g Q , O p p e r m a n T , H o u s e w e a r t C E ;
 W P I ; 2 0 0 6 - 7 4 4 0 5 0 / 7 6 .
 P - P S D B ; A E L 0 7 8 2 4 .
 N e w n u c l e i c a c i d e n c o d i n g S t r e p t o c o c c u s p n e u m o n i a e p o l y p e p t i d e , u s e f u l
 f o r d e t e c t i n g , p r e v e n t i n g , a n d t r e a t i n g p a t h o l o g i c a l c o n d i t i o n s r e s u l t i n g
 f r o m b a c t e r i a l i n f e c t i o n .
 E x a m p l e ; S E Q I D N O 1 0 9 6 ; 2 9 p p ; E n g l i s h .
 T h e i n v e n t i o n r e l a t e s t o a n i s o l a t e d n u c l e i c a c i d , e s p e c i a l l y (A E L 0 5 1 2 3) ,
 w h i c h e n c o d e s t h e S t r e p t o c o c c u s p n e u m o n i a e p r o t e i n o f A E L 0 7 7 8 4 . T h i s
 n u c l e i c a c i d i s o n e o f 2 6 6 1 d i s c l o s e d p r o t e i n - e n c o d i n g n u c l e i c a c i d s
 (A E L 0 4 0 6 8 - A E L 0 6 7 2 8) i s o l a t e d f r o m a S t r e p t o c o c c u s p n e u m o n i a e s t r a i n 1 4 4 5 3
 g e n o m i c l i b r a r y w h o s e p r e d i c t e d p r o d u c t s (A E L 0 6 7 2 9 - A E L 0 9 3 8 9) e x h i b i t
 h o m o l o g y t o k n o w n p r o k a r y o t i c , e u k a r y o t i c o r a r c h a e a l o p e n r e a d i n g f r a m e s
 (O R F s) o r p r o t e i n s . T h e i n v e n t i o n a l s o r e l a t e s t o a r e c o m b i n a n t
 e x p r e s s i o n v e c t o r c o m p r i s i n g t h e n u c l e i c a c i d o f t h e i n v e n t i o n o p e r a b l y
 l i n k e d t o a t r a n s c r i p t i o n r e g u l a t o r y e l e m e n t ; a n d a h o s t c e l l c o m p r i s i n g
 t h e r e c o m b i n a n t e x p r e s s i o n v e c t o r . T h e S t r e p t o c o c c u s p n e u m o n i a e n u c l e i c
 a c i d s a n d p r o t e i n s o f t h e i n v e n t i o n a r e u s e f u l f o r d i a g n o s i n g ,
 p r e v e n t i n g , o r t r e a t i n g p a t h o l o g i c a l c o n d i t i o n s r e s u l t i n g f r o m b a c t e r i a l
 i n f e c t i o n s , e s p e c i a l l y i n f e c t i o n s c a u s e d b y S t r e p t o c o c c u s p n e u m o n i a e s u c h
 a s m e n i n g i t i s , b a c t e r e m i a , p n e u m o n i a a n d o t i t i s m e d i a . T h e y m a y a l s o b e
 u s e d i n v a c c i n e c o m p o s i t i o n s f o r t h e t r e a t m e n t o f S t r e p t o c o c c u s
 p n e u m o n i a e i n f e c t i o n s a n d a s t a r g e t s f o r a n t i b a c t e r i a l d r u g s .
 A d d i t i o n a l l y t h e n u c l e i c a c i d s a r e u s e f u l i n t h e p r o d u c t i o n o f
 c o m m e r c i a l l y i m p o r t a n t p r o t e i n s s u c h a s e n z y m e s f o r u s e i n f e r m e n t a t i o n
 r e a c t i o n s o r i n t h e p r o d u c t i o n o f c o m m e r c i a l l y u s e f u l m e t a b o l i t e s . T h e
 p r e s e n t s e q u e n c e r e p r e s e n t s a S t r e p t o c o c c u s p n e u m o n i a e s t r a i n 1 4 4 5 3
 p r o t e i n - e n c o d i n g n u c l e i c a c i d w h i c h w a s i d e n t i f i e d i n t h e e x e m p l i f i c a t i o n
 o f t h e i n v e n t i o n . N o t e : T h e s e q u e n c e d a t a f o r t h i s p a t e n t d i d n o t f o r m
 p a r t o f t h e p r i n t e d s p e c i f i c a t i o n , b u t w a s o b t a i n e d i n e l e c t r o n i c f o r m a t
 d i r e c t l y f r o m t h e U S p a t e n t o f f i c e a t
 s e q d a t a . u s p t o . g o v / s e q u e n c e . h t m l ? D o c I D = 7 1 1 5 7 3 1 B 1 .
 S e q u e n c e 9 1 5 B P ; 2 7 9 A ; 1 7 5 C ; 2 2 0 G ; 2 4 1 T ; 0 U ; 0 O t h e r ;

Query Match 10.1% Score 76.4; DB 21; Length 915;
Best Local Similarity 50.5% Pred. No. 2.4e-13;
Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

Qy 31 CCATTTCTGACCAATGACCAAGTGAAA GATT TGATAGCCAAGAGCCAAAGCTGGCGATACG 90
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 328 OCTCTCTTGACCAATGAAGAGGAGAAAA GATT GGCACTGGCTGTGAAGCTGGT GATATC 387
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy 91 GATGCAOGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCOGTCGTCCAGGCG 150
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 388 GAAGGCCAAACAACGCTCTTGCGGAAGGCCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447

AEL12413

XX

XX

XX

XX

KW

KW

KW

XX

XX

FT

FT

FT

XX

XX

XX

XX

PR

PR

PR

PR

XX

XX

XX

DR

XX

PT New isolated nucleic acid and polypeptide isolated from strain 14453 of
PT Streptococcus pneumoniae, useful for diagnosing, preventing, or treating
PT bacterial infections, e.g. S. pneumoniae infection.

XX
PS Example; SEQ ID NO 1096; 29pp; English.

XX
CC The invention relates to an isolated nucleic acid, especially (AEL12919),
CC which encodes the Streptococcus pneumoniae protein of AEL15580. This
CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
CC (AEL11318-AEL13978) isolated from a Streptococcus pneumoniae strain 14453
CC genomic library whose predicted products (AEL13979-AEL16639) exhibit
CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
CC (ORFs) or proteins. The invention also relates to a recombinant
CC expression vector comprising the nucleic acid of the invention operably
CC linked to a transcription regulatory element; and a host cell comprising
CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
CC acids and proteins of the invention are useful for diagnosing,
CC preventing, or treating pathological conditions resulting from bacterial
CC infections, especially infections caused by Streptococcus pneumoniae such
CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
CC used in vaccine compositions for the treatment of Streptococcus
CC pneumoniae infections and as targets for antibacterial drugs.
CC Additionally the nucleic acids are useful in the production of
CC commercially important proteins such as enzymes for use in fermentation
CC reactions or in the production of commercially useful metabolites. The
CC present sequence represents a Streptococcus pneumoniae strain 14453
CC protein-encoding nucleic acid which was identified in the exemplification
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from the US patent office at
CC seqdata.uspto.gov/sequence.html?DocID=7122368B1.

XX
SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
Best Local Similarity 50.5% Pred. No. 2.4e-13;
Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
          |||
Db      328 OCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387

Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTGTCAGCGC 150
          |||
Db      388 GAAGCCAAACAACGTCTTGCGGAAGCCAATCTTGGTTGTTTGCATTGCCAAACGC 447

Qy     151 TTTATCAACCGGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
          |||
Db     448 TATGTGGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGCTTGATG 507

Qy     211 AAGGCGGTTGACAAGTTGATCTTTGACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
          |||
Db     508 AAGGCGGTTGACAAGTTGACTATTCTAAAGGTTCAAGTTTCAACTATGCAACTTGG 567

Qy     271 ATGATCATCGGAGAAATTCACGCTTTTGGCGGATGACG - - GTACGGTTAAGGTCAGT 327
          |||
Db     568 TGGATTGTCAGGCTATCACTGCTGCTATTGCAGACCAAGCTCGTACCATCGTATCCCA 627

Qy     328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
          |||
Db     628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACACCGGAATCTCCTTCAAGAA 687

Qy     388 TTCGGCGGTGCCCCACGATCGCAGAAGTGGCAGAAGCAGTGGGAATCACGCGGAGGAA 447
          |||
Db     688 TTGGGCAAGATCCGACACCAAGACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747

Qy     448 GT 449
          ||
Db     748 GT 749

```

RESULT 15

AEL50821

ID AEL50821 standard; DNA; 915 BP.

XX

AC AEL50821;

XX

DT 28-DEC-2006 (first entry)

XX

DE Streptococcus pneumoniae strain 14453 protein-encoding DNA, SEQ: 1096.

XX

KW Vaccine; diagnosis; drug discovery; protein production;

KW bacterial infection; Streptococcus pneumoniae infection;

KW bacterial meningitis; bacterial pneumonia; bacteremia; otitis media;

KW antibacterial; neuroprotective; antiinflammatory; respiratory-gen.;

KW auditory; gene; ds.

XX

OS Streptococcus pneumoniae; strain 14453.

XX

FH Key Location/Qualifiers

FT CDS

1..915

FT /*tag= a

FT /product= "Streptococcus pneumoniae protein SEQ ID

FT NO: 3757"

XX

PN US7129340-B1.

XX

PD 31-OCT-2006.

XX

PF 30-DEC-2004; 2004US-00028457.

XX

PR 02-JUL-1997; 97US-0051553P.

PR 12-MAY-1998; 98US-0085131P.

PR 30-JUN-1998; 98US-00107433.

PR 26-MAY-2000; 2000US-00583110.

PR 14-AUG-2003; 2003US-00640833.

XX

PA (SNFI) SANOFI PASTEUR LTD.

XX

PI Doucette-Stamm L, Bush D, Zeng Q, Opperman T, Houseweart CE;

XX

DR WPI; 2006-812716/82.

DR P-PSDB; AEL53482.

XX

PT New isolated nucleic acid and polypeptide isolated from Streptococcus
 PT pneumoniae, useful as components of antibacterial vaccines, and for
 PT diagnosing or treating S. pneumoniae and other Streptococcus infections.

XX

PS Example; SEQ ID NO 1096; 29pp; English.

XX

CC The invention relates to an isolated nucleic acid, especially (AEL52290),
 CC which encodes the Streptococcus pneumoniae protein of AEL54951. This
 CC nucleic acid is one of 2661 disclosed protein-encoding nucleic acids
 CC (AEL49726-AEL52386) isolated from a Streptococcus pneumoniae strain 14453
 CC genomic library whose predicted products (AEL52387-AEL55047) exhibit
 CC homology to known prokaryotic, eukaryotic or archaeal open reading frames
 CC (ORFs) or proteins. The invention also relates to a recombinant
 CC expression vector comprising the nucleic acid of the invention operably
 CC linked to a transcription regulatory element; and a host cell comprising
 CC the recombinant expression vector. The Streptococcus pneumoniae nucleic
 CC acids and proteins of the invention are useful for diagnosing,
 CC preventing, or treating pathological conditions resulting from bacterial
 CC infections, especially infections caused by Streptococcus pneumoniae such
 CC as meningitis, bacteremia, pneumonia and otitis media. They may also be
 CC used in vaccine compositions for the treatment of Streptococcus
 CC pneumoniae infections and as targets for antibacterial drugs.
 CC Additionally the nucleic acids are useful in the production of
 CC commercially important proteins such as enzymes for use in fermentation

CC reactions or in the production of commercially useful metabolites. The
 CC present sequence represents a *Streptococcus pneumoniae* strain 14453
 CC protein-encoding nucleic acid which was identified in the exemplification
 CC of the invention. Note: The sequence data for this patent did not form
 CC part of the printed specification, but was obtained in electronic format
 CC directly from the US patent office at
 CC seqdata.uspto.gov/sequence.html?DocID=7129340B1.

XX

SQ Sequence 915 BP; 279 A; 175 C; 220 G; 241 T; 0 U; 0 Other;

Query Match 10.1% Score 76.4; DB 21; Length 915;
 Best Local Similarity 50.5% Pred. No. 2.4e-13;
 Matches 213; Conservative 0; Mismatches 206; Indels 3; Gaps 1;

```

Qy      31 CCATTTCTGACCAATGACCAAGTGAAAGATTTGATAGCCAAGAGCCAAGCTGGCGATACG 90
      |||
Db      328 CCTCTCTTGACCAATGAAGAGGAGAAAGAGTTGGCACTGGCTGTTGAAGCTGGTGATATC 387
Qy      91 GATGCACGTGAGCTTCTCGTGAATAGCAATATCAGACTGGTCTGGTCCGTCGTCCAGCGC 150
      |||
Db      388 GAAGCCAAACAACGTCTTGCGGAAGCCAATCTTCGTTTGGTTGTTTCCATTGCCAAACGC 447
Qy     151 TTTATCAACCGCGGGTATGAAGCGGATGATTTGTTTCAGATCGGTTGCATTGGCTTGCTC 210
      |||
Db     448 TATGTGGTGGTGGTATGCAGTTCCTTGACTTGATTCAAGAAGGAAATATGGGCTTGATG 507
Qy     211 AAGGCGGTTGACAAGTTCGATCTTTCGTACGATGTGAGATTTTCGACCTATGCGGTGCCA 270
      |||
Db     508 AAGGCGGTTGACAAGTTTGACTATTCTAAAGGGTCAAGTTTCAACTTATGCAACTTGG 567
Qy     271 ATGATCATCGGAGAAATTCAACGCTTTTTGCGCGATGACG - - GTACGGTTAAGGTCAGT 327
      |||
Db     568 TGGATTOGTGAGGCTATCACTOGTGCTATTGCAGACCAAGCTCGTAACATCGTATCCCA 627
Qy     328 CGATCGTTAAAAGAAACAGCGAATAAGGTGCGGCGATCAAAGGATGAATTGTACAAGCAA 387
      |||
Db     628 GTTCACATGGTTGAAACTATCAATAAATTGGTTCGTGAACAGCGGAATCTCCTTCAAGAA 687
Qy     388 TTGGGCGGTGCCCCACGATCGCAGAAGTGCCAGAAGCAGTGGGAATCACGCGGAGGAA 447
      |||
Db     688 TTGGGGCAAGATCCGACACCAGAACAGATTGCTGAACGAATGGATATGACACCTGATAAG 747
Qy     448 GT 449
      ||
Db     748 GT 749
  
```

Search completed: November 4, 2008, 17:14:39
 Job time : 247 secs

SCORE 3.0